Unlock instant, AI-driven research and patent intelligence for your innovation.

Liposome encapsulated affinity drug

A liposome and affinity technology, applied in liposome delivery, drug combination, drug delivery, etc., can solve the problem of losing the advantage of antifolates

Inactive Publication Date: 2017-05-31
L E A F HLDG GRP
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recently, due to the availability of newer alternative treatments for cancer, antifolates have lost their edge over these therapies despite their superior effectiveness in killing cancer cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liposome encapsulated affinity drug
  • Liposome encapsulated affinity drug
  • Liposome encapsulated affinity drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] Example 1: Production of folate receptor alpha targeting liposomes containing pemetrexed and hapten

[0155] Production of Pemetrexed Liposomes

[0156] Pemetrexed disodium heptahydrate (ALIMTA) is highly water soluble with a solubility of 100 mg / ml at neutral pH. Pemetrexed was encapsulated in liposomes by the following steps. First, the lipid components of the liposome membranes are weighed and combined as a concentrated solution in ethanol at about 65°C. In this example, the lipids used were hydrogenated soybean phosphatidylcholine, cholesterol, DSPE-PEG-2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy base (polyethylene glycol)-2000]), PEG-DSPE-maleimide and PEG-DSPE-FITC. The molar ratio of HSPC:cholesterol:PEG-DSPE is about 55:40:5. Next, pemetrexed was dissolved in an aqueous buffer at a concentration of 100 mg / ml. The drug solution was heated to 65°C. Inject the ethanolic lipid solution into the pemetrexed solution using a small-bore ne...

Embodiment 2

[0166] Example 2: Cell lines used in experiments

[0167] Cell lines used in experiments are commercially available from sources such as ATCC (American Type Culture Collection, Manassas, VA, USA). The cell lines, their ATCC accession numbers and growth conditions are listed below.

[0168] Calu-3 (ATCC HTB-55); EMEM (Cat. #30-2003); 10% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

[0169] KB; EMEM (Cat. #30-2003); 10% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

[0170] CCD841 (ATCC CRL-1790); EMEM (Cat. #30-2003); 10% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

[0171] Hs578Bst (ATCC HTB-125); Hybri-Care medium pH 7.0 (Cat. #46-X); 30 ng / ml mouse EGF; 10% HI FBS; 1% Pen / Strep;

[0172] NCI-H2087 (ATCC CRL-5922); RPMI-1640 (Cat. #30-2001); 5% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

[0173] NCI-H2452 (ATCC CRL-5946); RPMI-1640 (Cat. #30-2001); 10% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

[0174] OVCAR-3 (ATCC HTB-161); RPMI-1640 (Cat. #30-2001); 20% HI FBS; 1% Pen / Strep; 1% L-Glutamine.

...

Embodiment 3

[0178] Example 3: Determining the binding specificity of a sample construct

[0179] The level of folate receptor alpha on the cell surface was measured by flow cytometry using a monoclonal antibody conjugated to a fluorescent dye. Lines prior to antibody treatment (see e.g. Figure 6 , lines 602 and 604) compared to after antibody binding (see e.g. Figure 6 , line 606) indicates detection of the receptor by flow cytometry. Histogram (eg, Figure 6 , line 606) relative to untreated cells (see e.g. Figure 6 , lines 602 and 604) shift to the more to the right, the higher the level of receptors on the cell surface. The figure shows high levels of folate receptor alpha on cancer cells, but barely detectable levels on normal cells.

[0180] Exemplary liposomes, as part of an exemplary liposome composition constructed, bind to the cell surface of cells that are folate receptor alpha positive but not folate receptor alpha negative. Exemplary liposomes contain antibodies to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
number average molecular weightaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The disclosure provides a liposomal antifolate composition comprising a liposome including an interior space, a bioactive antifolate agent disposed within said interior space, a steric stabilizer attached to an exterior of the liposome, and a targeting moiety comprising a protein with specific affinity for at least one folate receptor, said targeting moiety attached to at least one of the steric stabilizer and the exterior of the liposome.

Description

[0001] related application [0002] This application claims U.S. Provisional Application No. 62 / 037,597, filed August 14, 2014, U.S. Provisional Application No. 62 / 130,493, filed March 9, 2015, and U.S. Provisional Application No. 62 / 133,265 entitlement. The entire contents of each of these applications are incorporated by reference. Background technique [0003] Cancer is a very difficult disease to treat due to the diversity of cancer types, mechanisms involved in disease progression, and patient variability associated with the underlying patient genetic makeup. Early efforts to treat cancer involved the use of cytotoxic agents, including antifolates. Antifolates refer to a class of molecules that antagonize (ie block) the action of folic acid (vitamin B9). The main function of folic acid in the body is to act as a cofactor for various methyltransferases involved in the biosynthesis of serine, methionine, thymidine and purine. Antifolates thus inhibit cell division, DNA / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/195
CPCA61K9/0019A61K9/1271A61K47/6849A61K47/6913A61K31/519A61K45/06C07K16/28C07K2317/40C07K2317/77A61P35/00A61P37/04A61K2300/00A61K9/1278A61K9/19A61K47/12A61K47/26A61K9/08
Inventor C·尼基萨J·瓦尔盖瑟
Owner L E A F HLDG GRP